COLLEGIUM PHARMACEUTICAL, INC 8-K

What Happened Collegium Pharmaceutical, Inc. (COLL) filed an 8‑K reporting that on April 6, 2026 the Board approved the nomination of Michael Donovan to stand for election at the company’s 2026 Annual Meeting of Shareholders. Separately, on April 2, 2026 director John Fallon, M.D., informed the Board he will not stand for re‑election and will retire from the Board at the Annual Meeting. The company said Dr. Fallon’s decision is part of board refreshment and not due to any disagreement with the company.

Key Details

• Nominee: Michael Donovan, age 60; audit Partner at Ernst & Young LLP since 2002.
• Donovan roles: Office Managing Partner, EY’s biotechnology office in Kendall Square (2014–2024) and East Region Biotechnology Leader; active Certified Public Accountant; B.S. in Business Administration from Merrimack College.
• Retirement: John Fallon has served as a director since 2016 and will remain on the Board until the 2026 Annual Meeting.
• Filing: Reported on Form 8‑K (Item 5.02); signatures show the filing dated April 2, 2026 (filed April 7, 2026).

Why It Matters This is a board-level governance change—adding a nominee with deep audit and life‑sciences financial experience while losing a director who served since 2016. For investors, the changes bear on board composition, oversight and succession planning but do not indicate any dispute with management. Watch the company’s proxy materials and the 2026 Annual Meeting outcome for confirmation of Donovan’s election and any further board changes.